Provided by Tiger Fintech (Singapore) Pte. Ltd.

Coherus BioSciences

1.18
-0.0500-4.07%
Volume:1.78M
Turnover:2.16M
Market Cap:137.15M
PE:0.76
High:1.26
Open:1.23
Low:1.17
Close:1.23
52wk High:2.43
52wk Low:0.6603
Shares:116.23M
Float Shares:111.19M
Volume Ratio:1.21
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.55
EPS(LYR):0.2489
ROE:331.11%
ROA:-9.92%
PB:1.14
PE(LYR):4.74

Loading ...

Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21%

Simply Wall St.
·
Aug 10

Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Coherus (CHRS) Q2 Revenue Jumps 10%

Motley Fool
·
Aug 08

Coherus BioSciences Q2 Adj. EPS $(0.34) Misses $(0.28) Estimate, Sales $10.254M Miss $10.946M Estimate

Benzinga
·
Aug 08

Coherus BioSciences Q2 Adjusted EPS USD 116077710

Reuters
·
Aug 08

Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025, Non-GAAP Net Loss Widens to $39 Million

Reuters
·
Aug 08

Coherus BioSciences Q2 Sales USD 10.254 Million VS. Ibes Estimate USD 10.1 Million

THOMSON REUTERS
·
Aug 08

Corrected-Coherus BioSciences Q2 Adjusted EPS USD -0.34 (Corrects Amount)

THOMSON REUTERS
·
Aug 08

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 08

Coherus Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Aug 06

Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year

Simply Wall St.
·
Jul 14

Truist Financial Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)

TIPRANKS
·
Jul 09

Coherus Oncology Inc. Receives Nasdaq Deficiency Notice for Falling Below Minimum Bid Price Requirement

Reuters
·
Jul 04

Coherus Oncology Inc. Conducted Annual Stockholders Meeting Virtually

Reuters
·
Jun 14

Coherus Biosciences completes transformation to Coherus Oncology

TIPRANKS
·
May 30

BRIEF-Coherus Completes Strategic Transformation To Coherus Oncology

Reuters
·
May 30

Coherus BioSciences Rebrands as Coherus Oncology, Emphasizing Cancer Therapeutics

Reuters
·
May 30

Maxim Group Sticks to Its Hold Rating for Coherus Biosciences (CHRS)

TIPRANKS
·
May 30

Director Mats Wahlstrom Reports Disposal of Coherus BioSciences Inc. Common Shares

Reuters
·
May 29

Coherus BioSciences Announces Launch of Phase 1b/2 Clinical Trial for LOQTORZI and STC-15 Combination Targeting Various Cancers

Reuters
·
May 27